CA
NZ
UK
AU
IND
US
Onconetix, Inc. has authorized up to 42,000 shares of Series F Preferred Stock, significantly impacting its capital structure. This move offers investors potential for conversion at an initial price of $0.9767, amidst a challenging market landscape.Key HighlightsThe company has already issued 37,812 shares to …
delivered earnings per share of $-0.43 for the quarter ended June 30, markedly better than the consensus estimate of $-1.09. The earnings beat came alongside a 56% jump in revenue, highlighting the commercial lift from newly launched products and expanding partnership royalties. Investors see …
Milestone Scientific Inc. (NYSE American: MLSS) announced that three of its directors have submitted conversion notices covering substantial portions of the company’s convertible bridge notes. The notices represent principal amounts of $116,495.47, $58,247.73 and $291,238.66 respectively, and will become effective once the common stock’s …
The stock saw its shares rise by 0.2%, reaching $51.50 in pre-market trading after JPMorgan offered a positive outlook for healthcare stocks. The investment bank highlighted several stocks in the sector as top picks, igniting interest among investors, especially those looking for resilient sectors …
The results featured earnings per share that outperformed consensus estimates, alongside revenue of $22.8 million, a 5% decline year‑over‑year. U.S. sales contributed $14.2 million, while international sales amounted to $8.6 million.
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported an earnings per share loss of $-1.10. This figure is an improvement over the consensus estimate of $-1.27 and indicates that the company is slightly better positioned than analysts had anticipated. The reported EPS reflects continued investment in …
Integra LifeSciences Holdings Corporation (NASDAQ: IART) delivered a solid financial performance for the second quarter, indicating resilience in the competitive healthcare environment. The company reported revenues of $418.8 million for the quarter ending June 30, 2026, reflecting a 0.8% increase compared to the same …
Longeveron Inc. has reinstated its Audit Committee, now comprising four independent directors, including one financial expert. This move restores compliance with Nasdaq regulations and signals the company's commitment to strong governance, which may enhance investor confidence.Key HighlightsLongeveron Inc. reconstituted its Audit Committee, appointing four …
Has just delivered a strong performance. For the quarter ended, the company reported earnings per share (EPS) of $0.50, which notably exceeded the consensus estimate of $0.48. This result highlights the company's ability to navigate market challenges and deliver value to shareholders.
PetVivo Holdings has announced the conclusion of its exclusive licensing arrangement with VetStem, accompanied by a cash settlement of $75,000. Under the terms of the Settlement Agreement, the parties have agreed to release each other from all royalty, milestone and invoice obligations, with the …
Please wait processing your request...